Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae announces debt transaction to refinance 2024 notes. Q4 results decent as ongoing restructuring continues. 2023 guidance could have been better. For the quarter, revenue came in at $122.45 ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae's shares have plummeted as the company slashed its growth forecast to avoid bankruptcy. Revenue for Q2 was slightly above estimates but down 12% YoY, and analyst revenue estimates have ...

Shares of the genetic testing company have more than doubled in less than a week. It likely isn’t durable. It was also truly bizarre. Invitae announced a strategic pivot and provided financial ...

Shares of molecular diagnostics company Invitae (NYSE: NVTA) climbed 10.7% on Tuesday. At this point, investors may be more willing to take a flyer on Invitae, especially since Cathie Wood, the CEO ...

The medical genetics specialist posted an earnings beat in the second quarter. New guidelines on genetic testing for colorectal cancer should helps Invitae. Still, the market’s reaction seems ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...

The shares of genetic testing concern InVitae Corp (NYSE:NVTA) are fresh off an all-time high of $28.38, last seen 1.6% higher at $27.60, thanks to a boost from Citron Research. The firm said it will ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...